Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Investor Update with One of the Largest Education & Student Housing Investment Companies In Canada

While many businesses have struggled during COVID-19 and now the Omicron variant, there have been some that have prospered, and even increased their business. Vancouver-based, CIBT Education Group Inc. (MBA) ( TSX.MBA , OTCQX: MBAIF , Forum ) is one of those compani...
Dave Jackson | February 18, 2022 |

Alasdair Macleod Wants to Invent a New Form of Math

I lived in California when I was in the 7 th grade. The state led the rest of the US in education. That was before it turned into a socialist paradise. I took an algebra course in the 7 th grade; California would let you take any course the teacher would allow you in. I...
Streetwise Reports | March 23, 2020 |

A psychedelic renaissance

Fifty-three years after LSD was banned by the FDA, psychedelic drugs are making a comeback. Only instead of being the pills, mushrooms and acid tabs that helped college students to “turn on, tune in, drop out” Timothy Leary-style, today’...
Richard (Rick) Mills | December 3, 2019 |

10 Million Americans Applied for Unemployment Benefits. Will Gold Save the Day?

In just two weeks of March, around 10 million Americans applied for unemployment benefits. That’s more than during the Great Recession. What does it imply for the US economy and the gold market? US Labor Market Sinks In the previous edition of the Fundam...
Arkadiusz Sieron | April 7, 2020 |

Karuna Shares Jump 375% Higher on Phase 2 Acute Psychosis Treatment Trial Data

Shares of Karuna Therapeutics, which completed an IPO in July 2019, soared more than 375% higher today after the firm reported that its KarXT met primary endpoint in a phase 2 clinical trial of acute psychosis in patients with schizophrenia. This morning clinical-stag...
Streetwise Reports | November 19, 2019 |

AI & Humor in the Workplace … A Laughing Matter?

We have all worried about “robots taking our jobs”, but working in a creative field, I’ve always had a high-and-mighty belief that no mere machine could do what I do … until they could. Running a certain set of parameters through an ar...
According to published reports | September 1, 2021 |

HAVN Life Sciences: Using psychedelics, specifically mushrooms, to improve mental health

Mental health, as we know, controls a large part of how we interact with the world around us. Our next guest knows this and is working to improve the mental health of those struggling by using psychedelics, specifically mushrooms. Psychedelics are not federally l...
Brieanna McCutcheon | November 4, 2022 |

Soliton Shares Rise on Announcement It Will Report Clinical Data at National Dermatology Conference

Soliton Inc. shares traded 10% higher today after advising that later this month it will present the data from clinical trials for its Rapid Acoustic Pulse device used in the treatment of keloid and hypertrophic scars at the American Society for Dermatologic Surgery Annual Mee...
Streetwise Reports | October 10, 2019 |

Intra-Cellular Therapies Shares Rise 200% on FDA Approval of Adult Schizophrenia Drug

Shares of Intra-Cellular Therapies opened greater than 100% higher today after the company reported that the FDA approved its antipsychotic CAPLYTA® (lumateperone) drug for the treatment of schizophrenia in adults. This morning a biopharmaceutical company foc...
Streetwise Reports | December 27, 2019 |

Novamind’s Trial Site for Merck Another Example Of Its Leadership in Mental Health

Novamind’s clinics and clinical research capabilities are already well established to bring alternative mental health therapies, including psychedelic medicine, to market. One of the world’s largest pharmaceutical companies has selected ...
Featured Submission | March 24, 2021 |
1 2 3 4 5 6 7 8 9 10 ...